



**During the quarter the company has received the following 10 ANDA approvals.**

Terbinafine HCl Tablets (250 mg)	Amlodipine Besylate Tablets (25 & 50 mg)
Hydrochlorothiazide Tablets (12.5 mg)	Paroxetine Tablets (10,20,30 & 30 mg)
Ondasetron HCl Tablets (4,8 & 24 mg)	Quinapril HCl + Hydrochlorothiazide (10/12.5,20/12.5 & 20/25 mg)
Carvedilol Tablets (3.125, 6.25, 12.5 & 25 mg)	Topiramate Tablets (25, 50, 100 & 200 mg),
Metoprolol Tartrate Tablets USP (25,50 & 100mg)	Hydrochlorothiazide Capsules (12.5 mg)

**The global regulatory filings are as under:**

Filings	Q2 FY 07-08	Cumulative Filings as on 30th September 2007
ANDAs (USA)	12	106
DMFs (USA)	5	117
Formulations Dossiers in other key regulated markets	12	163
API Dossier filings in other key regulated markets	166	698
Patents	15	281

54 ANDAs have been approved as on 30th September 2007.

**AUROBINDO PHARMA LTD**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.